Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Thirty-year risk of ischemic stroke in individuals with sickle cell trait and modification by chronic kidney disease: The atherosclerosis risk in communities (ARIC) study.

Caughey MC, Derebail VK, Key NS, Reiner AP, Gottesman RF, Kshirsagar AV, Heiss G.

Am J Hematol. 2019 Aug 19. doi: 10.1002/ajh.25615. [Epub ahead of print]

PMID:
31429114
2.

A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell disease.

Ataga KI, Wichlan D, Elsherif L, Derebail VK, Wogu AF, Maitra P, Cai J, Caughey MC, Pollock DM, Pollock JS, Archer DR, Hinderliter AL.

Am J Hematol. 2019 Nov;94(11):E299-E301. doi: 10.1002/ajh.25614. Epub 2019 Aug 22. No abstract available.

PMID:
31407373
3.

Association of sickle cell trait with measures of cognitive function and dementia in African Americans.

Chen N, Caruso C, Alonso A, Derebail VK, Kshirsagar AV, Sharrett AR, Key NS, Gottesman RF, Grove ML, Bressler J, Boerwinkle E, Windham BG, Mosley TH Jr, Hyacinth HI.

eNeurologicalSci. 2019 Jul 22;16:100201. doi: 10.1016/j.ensci.2019.100201. eCollection 2019 Sep.

4.

Rapid decline in estimated glomerular filtration rate is common in adults with sickle cell disease and associated with increased mortality.

Derebail VK, Zhou Q, Ciccone EJ, Cai J, Ataga KI.

Br J Haematol. 2019 Sep;186(6):900-907. doi: 10.1111/bjh.16003. Epub 2019 Jun 5.

PMID:
31168785
5.

Glomerular Filtration: Too Much of a Good Thing?

Mottl AK, Hostetter TH, Derebail VK.

Am J Kidney Dis. 2019 Jun;73(6):756-758. doi: 10.1053/j.ajkd.2019.01.039. No abstract available.

PMID:
31126413
6.

Progressive Decline in Estimated GFR in Patients With Sickle Cell Disease: An Observational Cohort Study.

Derebail VK, Ciccone EJ, Zhou Q, Kilgore RR, Cai J, Ataga KI.

Am J Kidney Dis. 2019 Jul;74(1):47-55. doi: 10.1053/j.ajkd.2018.12.027. Epub 2019 Feb 21.

PMID:
30797615
7.

Effect of renin-angiotensin-aldosterone system blocking agents on progression of glomerulopathy in sickle cell disease.

Thrower A, Ciccone EJ, Maitra P, Derebail VK, Cai J, Ataga KI.

Br J Haematol. 2019 Jan;184(2):246-252. doi: 10.1111/bjh.15651. Epub 2018 Nov 21.

PMID:
30460977
8.

Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy.

Reynolds ML, Nachman PH, Mooberry MJ, Crona DJ, Derebail VK.

J Nephrol. 2019 Aug;32(4):669-672. doi: 10.1007/s40620-018-0552-9. Epub 2018 Nov 12.

PMID:
30421320
9.

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.

Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R; DUET Study Group.

J Am Soc Nephrol. 2018 Nov;29(11):2745-2754. doi: 10.1681/ASN.2018010091.

10.

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).

Komers R, Gipson DS, Nelson P, Adler S, Srivastava T, Derebail VK, Meyers KE, Pergola P, MacNally ME, Hunt JL, Shih A, Trachtman H.

Kidney Int Rep. 2017 Mar 4;2(4):654-664. doi: 10.1016/j.ekir.2017.02.019. eCollection 2017 Jul.

11.

The spectrum of sickle hemoglobin-related nephropathy: from sickle cell disease to sickle trait.

Naik RP, Derebail VK.

Expert Rev Hematol. 2017 Dec;10(12):1087-1094. doi: 10.1080/17474086.2017.1395279. Epub 2017 Oct 30. Review.

12.

Renal Medullary Carcinoma: Establishing Standards in Practice.

Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK.

J Oncol Pract. 2017 Jul;13(7):414-421. doi: 10.1200/JOP.2017.020909. Review.

13.

Sickle Cell Trait and the Risk of ESRD in Blacks.

Naik RP, Irvin MR, Judd S, GutiƩrrez OM, Zakai NA, Derebail VK, Peralta C, Lewis MR, Zhi D, Arnett D, McClellan W, Wilson JG, Reiner AP, Kopp JB, Winkler CA, Cushman M.

J Am Soc Nephrol. 2017 Jul;28(7):2180-2187. doi: 10.1681/ASN.2016101086. Epub 2017 Mar 9.

14.

A Randomized Crossover Trial of Dietary Sodium Restriction in Stage 3-4 CKD.

Saran R, Padilla RL, Gillespie BW, Heung M, Hummel SL, Derebail VK, Pitt B, Levin NW, Zhu F, Abbas SR, Liu L, Kotanko P, Klemmer P.

Clin J Am Soc Nephrol. 2017 Mar 7;12(3):399-407. doi: 10.2215/CJN.01120216. Epub 2017 Feb 16.

15.

Sickle cell trait is not associated with an increased risk of heart failure or abnormalities of cardiac structure and function.

Bello NA, Hyacinth HI, Roetker NS, Seals SR, Naik RP, Derebail VK, Kshirsagar AV, Key NS, Wilson JG, Correa A, Adams RJ, Egede LD, Longstreth WT Jr, Choudhary G, Gee BE, Hughes AL, Shah AM, Manson JE, Allison M, Burke GL, Folsom AR, Carty CL, Reiner AP, Solomon SD, Konety SH.

Blood. 2017 Feb 9;129(6):799-801. doi: 10.1182/blood-2016-08-705541. Epub 2016 Dec 8. No abstract available.

16.

Albuminuria Is Associated with Endothelial Dysfunction and Elevated Plasma Endothelin-1 in Sickle Cell Anemia.

Ataga KI, Derebail VK, Caughey M, Elsherif L, Shen JH, Jones SK, Maitra P, Pollock DM, Cai J, Archer DR, Hinderliter AL.

PLoS One. 2016 Sep 26;11(9):e0162652. doi: 10.1371/journal.pone.0162652. eCollection 2016.

17.

Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS.

Laurin LP, Gasim AM, Derebail VK, McGregor JG, Kidd JM, Hogan SL, Poulton CJ, Detwiler RK, Jennette JC, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1752-1759. doi: 10.2215/CJN.13091215. Epub 2016 Jul 21.

18.

Proceedings of a Sickle Cell Disease Ontology workshop - Towards the first comprehensive ontology for Sickle Cell Disease.

Mulder N, Nembaware V, Adekile A, Anie KA, Inusa B, Brown B, Campbell A, Chinenere F, Chunda-Liyoka C, Derebail VK, Geard A, Ghedira K, Hamilton CM, Hanchard NA, Haendel M, Huggins W, Ibrahim M, Jupp S, Kamga KK, Knight-Madden J, Lopez-Sall P, Mbiyavanga M, Munube D, Nirenberg D, Nnodu O, Ofori-Acquah SF, Ohene-Frempong K, Opap KB, Panji S, Park M, Pule G, Royal C, Sangeda R, Tayo B, Treadwell M, Tshilolo L, Wonkam A.

Appl Transl Genom. 2016 Mar 15;9:23-9. doi: 10.1016/j.atg.2016.03.005. eCollection 2016 Jun.

19.

Patients with primary membranous nephropathy are at high risk of cardiovascular events.

Lee T, Derebail VK, Kshirsagar AV, Chung Y, Fine JP, Mahoney S, Poulton CJ, Lionaki S, Hogan SL, Falk RJ, Cattran DC, Hladunewich M, Reich HN, Nachman PH.

Kidney Int. 2016 May;89(5):1111-1118. doi: 10.1016/j.kint.2015.12.041. Epub 2016 Feb 26.

20.

Negative health implications of sickle cell trait in high income countries: from the football field to the laboratory.

Key NS, Connes P, Derebail VK.

Br J Haematol. 2015 Jul;170(1):5-14. doi: 10.1111/bjh.13363. Epub 2015 Mar 7. Review.

21.

Prospective study of sickle cell trait and venous thromboembolism incidence.

Folsom AR, Tang W, Roetker NS, Kshirsagar AV, Derebail VK, Lutsey PL, Naik R, Pankow JS, Grove ML, Basu S, Key NS, Cushman M.

J Thromb Haemost. 2015 Jan;13(1):2-9. doi: 10.1111/jth.12787. Epub 2014 Dec 11.

22.

Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans.

Naik RP, Derebail VK, Grams ME, Franceschini N, Auer PL, Peloso GM, Young BA, Lettre G, Peralta CA, Katz R, Hyacinth HI, Quarells RC, Grove ML, Bick AG, Fontanillas P, Rich SS, Smith JD, Boerwinkle E, Rosamond WD, Ito K, Lanzkron S, Coresh J, Correa A, Sarto GE, Key NS, Jacobs DR, Kathiresan S, Bibbins-Domingo K, Kshirsagar AV, Wilson JG, Reiner AP.

JAMA. 2014 Nov 26;312(20):2115-25. doi: 10.1001/jama.2014.15063.

23.

Sickle cell trait and incident ischemic stroke in the Atherosclerosis Risk in Communities study.

Caughey MC, Loehr LR, Key NS, Derebail VK, Gottesman RF, Kshirsagar AV, Grove ML, Heiss G.

Stroke. 2014 Oct;45(10):2863-7. doi: 10.1161/STROKEAHA.114.006110. Epub 2014 Aug 19.

24.

Polyomavirus nephropathy: quantitative urinary polyomavirus-Haufen testing accurately predicts the degree of intrarenal viral disease.

Singh HK, Reisner H, Derebail VK, Kozlowski T, Nickeleit V.

Transplantation. 2015 Mar;99(3):609-15. doi: 10.1097/TP.0000000000000367.

25.

Adenovirus causing fever, upper respiratory infection, and allograft nephritis complicated by persistent asymptomatic viremia.

Lachiewicz AM, Cianciolo R, Miller MB, Derebail VK.

Transpl Infect Dis. 2014 Aug;16(4):648-52. doi: 10.1111/tid.12248. Epub 2014 Jun 26.

PMID:
24966111
26.

The glomerulopathy of sickle cell disease.

Ataga KI, Derebail VK, Archer DR.

Am J Hematol. 2014 Sep;89(9):907-14. doi: 10.1002/ajh.23762. Epub 2014 Jun 19. Review.

27.

Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure.

Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2014 May;9(5):905-13. doi: 10.2215/CJN.08290813. Epub 2014 Feb 27.

28.

Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose.

Derebail VK, Lacson EK Jr, Kshirsagar AV, Key NS, Hogan SL, Hakim RM, Mooney A, Jani CM, Johnson C, Hu Y, Falk RJ, Lazarus JM.

J Am Soc Nephrol. 2014 Apr;25(4):819-26. doi: 10.1681/ASN.2013060575. Epub 2014 Jan 23.

29.

Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy.

Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour SJ, Tannous S, Hladunewich MA, Hu Y, Poulton CJ, Mahoney SL, Charles Jennette J, Hogan SL, Falk RJ, Cattran DC, Reich HN, Nachman PH.

Kidney Int. 2014 Jun;85(6):1412-20. doi: 10.1038/ki.2013.476. Epub 2013 Dec 11.

30.

Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease.

Laurin LP, Nachman PH, Desai PC, Ataga KI, Derebail VK.

Nephrol Dial Transplant. 2014 Jun;29(6):1211-8. doi: 10.1093/ndt/gft295. Epub 2013 Sep 30.

31.

Diagnostic significance of peritubular capillary basement membrane multilaminations in kidney allografts: old concepts revisited.

Liapis G, Singh HK, Derebail VK, Gasim AM, Kozlowski T, Nickeleit V.

Transplantation. 2012 Sep 27;94(6):620-9.

32.

Venous thromboembolism in patients with membranous nephropathy.

Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN.

Clin J Am Soc Nephrol. 2012 Jan;7(1):43-51. doi: 10.2215/CJN.04250511. Epub 2011 Nov 10.

33.

Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients.

Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Rosamond WD, Kshirsagar AV.

Kidney Int. 2011 Nov;80(9):992-999. doi: 10.1038/ki.2011.247. Epub 2011 Aug 17.

34.

Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans.

Hicks PJ, Langefeld CD, Lu L, Bleyer AJ, Divers J, Nachman PH, Derebail VK, Bowden DW, Freedman BI.

Kidney Int. 2011 Dec;80(12):1339-43. doi: 10.1038/ki.2011.286. Epub 2011 Aug 17.

35.

Sickle-cell trait: novel clinical significance.

Key NS, Derebail VK.

Hematology Am Soc Hematol Educ Program. 2010;2010:418-22. doi: 10.1182/asheducation-2010.1.418. Review.

36.

High prevalence of sickle cell trait in African Americans with ESRD.

Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Kshirsagar AV.

J Am Soc Nephrol. 2010 Mar;21(3):413-7. doi: 10.1681/ASN.2009070705. Epub 2010 Jan 7.

37.

Sugar-sweetened soda consumption, hyperuricemia, and kidney disease.

Bomback AS, Derebail VK, Shoham DA, Anderson CA, Steffen LM, Rosamond WD, Kshirsagar AV.

Kidney Int. 2010 Apr;77(7):609-16. doi: 10.1038/ki.2009.500. Epub 2009 Dec 23.

38.

The Case: Acute kidney injury in a patient with P. carinii pneumonia.

Derebail VK, McGregor JG, Colindres RE, Singh HK, Kshirsagar AV.

Kidney Int. 2009 Apr;75(8):865-6. doi: 10.1038/ki.2008.667. No abstract available.

39.

Rituximab therapy for membranous nephropathy: a systematic review.

Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2009 Apr;4(4):734-44. doi: 10.2215/CJN.05231008. Epub 2009 Mar 11. Review.

40.

A rare cause of the pulmonary-renal syndrome: a case of atypical haemolytic-uraemic syndrome complicated by pulmonary haemorrhage.

Derebail VK, Parikh P, Jennette JC, Kshirsagar AV.

NDT Plus. 2008 Dec;1(6):417-419. Epub 2008 Sep 3.

41.

Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats.

Pollock DM, Derebail VK, Yamamoto T, Pollock JS.

Gen Pharmacol. 2000 May;34(5):337-42.

Supplemental Content

Loading ...
Support Center